A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)

Autor:	Charlie Zhang, Sara A. Hurvitz, Debra L. Lounsbury, Andrew M Wardley, Melinda L. Telli, Fran Visco, Peter A. Fasching, Nathalie Andrienne Lokker, Mark E. Robson, Judith Balmaña, Nicholas C. Turner
Předmět:	Cancer Research DNA repair business.industry Poly ADP ribose polymerase BRCA mutation medicine.disease Molecular biology Metastatic breast cancer Germline chemistry.chemical_compound PARP1 Oncology chemistry PARP inhibitor Cancer research medicine Talazoparib business
Zdroj:	ResearcherID
Popis:	TPS1108 Background: Poly-ADP-ribose polymerase (PARP) represents a family of enzymes of which at least two (PARP1 and PARP2) play important roles in DNA repair. PARP inhibition induces synthetic le...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c139258c4b6ebec839aeddaff610cebc http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358036904663&KeyUID=WOS:000358036904663 Zobrazit plný text záznamu